white hous urg drug price restraint aid demand pharmaceut firm social respons point chang busi climat drug industri bush administr friday weigh grow disput high cost aid drug assist secretari health human servic jame mason urg pharmaceut industri show greater restraint price life extend medic societ good outweigh good one compani mason said press confer nation aid confer mount term bulli pulpit mason also serv act surgeon gener ad compani manufactur drug got social respons mason comment underscor aid alter busi equat pharmaceut industri long accustom scientif regulatori hurdl drug compani must also confront unusu level scrutini public offici organ vocal increasingli sophist patient commun mason tri speed process would normal take place market forc competit product introduc said samuel isali new york drug industri consult govern scrutini aid drug price shine spotlight question drug price ill issu wait focal point aid provid said jean mcguir execut director aid action council washington note senat select committe age recent held hear price prescript drug stung charg profit fear price control maker aid drug respond new climat price reduct drug giveaway indig patient market public relat program aid activist crusad lower drug price hail mason comment especi signific come administr gener regard strong propon free market activist continu charg industri price concess suffici although acknowledg cannot know sure drug compani refus disclos detail data cost mason said govern slightest idea cost produc drug still ad drug appear social respons mason said administr studi sever mechan achiev goal lower price includ chang orphan drug law law provid financi incent compani develop medic rare disord emphas howev chang care craft avoid chill effect industri research despit two price reduct 20 sinc azt licens 1987 latest one come last month member act disrupt trade new york stock exchang burrough wellcom continu charg 6 000 year full dose drug azt antivir agent approv use human immunodefici viru caus aid anoth compani sharpli critic activist group lyphom quadrupl price pentamidin 99 vial compani began investig drug effect aerosol form ward aid relat pneumonia drug licens june drug develop orphan drug law provid seven year monopoli gener tax credit compani develop medic condit afflict fewer 200 000 patient howev current law drug retain orphan statu even though recent studi indic use earlier hiv diseas onset full blown aid govern offici estim azt might use 500 000 hiv infect patient see perhap flaw orphan drug law mason said provis modifi drug orphan statu size market grow unexpectedli ad jeffrey c warren vice presid commun pharmaceut manufactur assn washington warn would big mistak revis modifi law success law said drug compani undertaken develop 133 drug 170 rare disord maker aid drug say price justifi high expenditur research resort number tactic defus controversi drug price addit lower price azt burrough wellcom donat thousand dollar group nation aid network nation assn peopl aid nation minor aid council though specif quid pro quo three group refus sign august statement 17 aid organ call lower azt price organ sign statement previous turn donat burrough week lyphom unveil plan donat unspecifi amount pentamidin indig patient lyphom also hire consult jim foster gay polit activist member san francisco health commiss foster could reach comment busi plead compani case privat meet key aid leader confer week martin delaney director patient advocaci group project inform call lyphom drug giveaway pr gestur hand patient may benefit societi suffer drug overpr cost born insur policyhold taxpay brian tambi lyphom senior vice presid insist lyphom good public citizen lyphom jump aid market compani unwil crucifi paradox time drug compani clash activist price other form allianc hasten drug approv process bring new medicin market faster delaney project inform met last week offici genelab u food drug administr attempt speed develop glq 223 u version chines drug call compound q delaney group test member act new york chapter work close bristol myer squibb devis parallel track distribut scheme experiment antivir drug ddi savvier compani come understand patient commun alli move drug fda approv process said jim eigo member act treatment data committe